Evidence map›Paper›PMID 36617173›Full record

ArticleMolecular human reproduction2023

Comprehensive molecular analysis identifies eight novel variants in XY females with disorders of sex development.

Vinayak Kulkarni, Selvaa Kumar Chellasamy, Somprakash Dhangar, Jagdeeshwar Ghatanatti, Babu Rao Vundinti

Open access · greenAbstract read
In one paragraph

Article in Molecular human reproduction, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Profile ofFrontiers in endocrinology · 2025
    Review
  3. Case Report:Frontiers in endocrinology · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Absent Left Testis in a Young Boy.AACE endocrinology and diabetes
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Vinayak KulkarniDepartment of Anatomy, Lokmanya Tilak Municipal Medical College and General Hospital, Mumbai, India.
Selvaa Kumar ChellasamyBioinformatics Division, School of Biotechnology and Bioinformatics, D.Y. Patil Deemed to be University, Navi Mumbai, India.
Somprakash DhangarDepartment of Cytogenetics, ICMR-National Institute of Immunohematology, Mumbai, India.
Jagdeeshwar GhatanattiDepartment of Cytogenetics, ICMR-National Institute of Immunohematology, Mumbai, India.
Babu Rao VundintiDepartment of Cytogenetics, ICMR-National Institute of Immunohematology, Mumbai, India.ORCID 0000-0003-4783-2691
ICMR - National Institute of Immunohaemotology · IND.Y. Patil University · INLokmanya Tilak Municipal General Hospital and Lokmanya Tilak Municipal Medical College · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Disorders of sex development (DSD) are a group of clinical conditions with variable presentation and genetic background. Females with or without development of secondary sexual characters and presenting with primary amenorrhea (PA) and a 46,XY karyotype are one of the classified groups in DSD. In this study, we aimed to determine the genetic mutations in 25 females with PA and a 46,XY karyotype to show correlations with their phenotypes. Routine Sanger sequencing with candidate genes like SRY, AR, SRD5A2, and SF1, which are mainly responsible for 46,XY DSD in adolescent females, was performed. In a cohort of 25 patients of PA with 46,XY DSD, where routine Sanger sequencing failed to detect the mutations, next-generation sequencing of a targeted gene panel with 81 genes was used for the molecular diagnosis. The targeted sequencing identified a total of 21 mutations including 8 novel variants in 20 out of 25 patients with DSD. The most frequently identified mutations in our series were in AR (36%), followed by SRD5A2 (20%), SF1 (12%), DHX37 (4%), HSD17B3 (4%), and DMRT2 (4%). We could not find any mutation in the DSD-related genes in five (20%) patients due to complex molecular mechanisms in 46,XY DSD, highlighting the possibility of new DSD genes which are yet to be discovered in these disorders. In conclusion, genetic testing, including cytogenetics and molecular genetics, is important for the diagnosis and management of 46,XY DSD cases.

Indexed as

Disorder of Sex Development, 46,XYGonadal Dysgenesis, 46,XY3-Oxo-5-alpha-Steroid 4-DehydrogenaseFemaleGenetic TestingHumansMembrane ProteinsMutation3-Oxo-5-alpha-Steroid 4-DehydrogenaseMembrane ProteinsSRD5A2 protein, humanandrogen insensitivity syndromeARDHX37disorders of sex developmentDMRT2HSD17B3primary amenorrheaSF1SRD5A2SRY

Identifiers

PMID36617173
PMCPMC10167928
OpenAlexW4313706870

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.